Calvin Grant
Ophthalmology · Palos Heights, ILNPI 1679551014
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 35.1% of the total. Reporting peaked in 2021 at $1,003 and has fallen 97.5% since, to $25 in 2025.
Across 203 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- AbbVie$840
- Novartis$444
- Alcon$264
- Bausch & Lomb, A Division Of Bausch Health US, LLC$195
- Mallinckrodt Enterprises LLC$158
- plus $436 from 9 others
What the payments were for
- Food & beverage$3,49397%
- Education$1073%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 45 | $1,263 |
| AbbVie(2 entities) | 76 | $840 |
| Novartis | 30 | $444 |
| Alcon | 12 | $264 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $195 |
| Mallinckrodt Enterprises LLC | 9 | $158 |
| Aerie Pharmaceuticals, Inc. | 7 | $131 |
| Sun Pharmaceutical Industries Inc. | 4 | $77 |
| Shire North American Group Inc | 2 | $47 |
| Apellis Pharmaceuticals, Inc. | 2 | $44 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $17 |
How this compares
$3,600 in reported general payments places this provider in the 70th percentile of 773 ophthalmology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 37 | $20,401 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,438 |
| Ketorolac Tromethamine | 49 | $1,296 |
| Brimonidine Tartrate | 24 | $1,097 |
| Prednisolone Acetate | 23 | $1,091 |
| Dorzolamide Hcl | 38 | $604 |
| Latanoprost | 35 | $504 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $449 |
| Timolol Maleate | 23 | $257 |
| Diclofenac Sodium | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $840 | $25,84051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Palos Heights
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.